{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:16Z","timestamp":1789140676063,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Drug-induced agranulocytosis (DIA) is a rare but life-threatening hematologic disorder that demands increased clinical and research attention. This study aimed to provide the current overview of DIA for clinical guidance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using real-world data from FDA Adverse Event Reporting System (FAERS), we performed a disproportionality analysis to identify the drugs associated with agranulocytosis, employing the information component and reporting odds ratio algorithms. Logistic analysis was conducted to explore the confounding factors of DIA. Time-to-onset analysis was implemented to compare the adverse event onset time among different drugs. To comprehensively supplement and corroborate our disproportionality findings, we further conducted an umbrella review of systematic reviews (SRs). Five electronic databases were searched with SRs addressing DIA as an included adverse event. Two independent reviewers performed literature screening, data extraction, and quality assessment according to the preferred reporting items for systematic reviews and meta-analysis statement. The results of the included SRs were synthesized using qualitative analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The disproportionality analysis revealed that most identified DIA signals were for anticancer drugs. The top-five drugs with DIA signals by case number were methotrexate (6,462 cases), lenalidomide (5,722 cases), rituximab (5,691 cases), doxorubicin (4,391 cases), and carboplatin (4,371 cases). High-risk drugs (e.g., deferiprone), old age, and abnormal weight were strongly associated with DIA based on multivariate logistic regression. Time-to-onset analysis showed that clozapine has the longest median of onset time (1,121.3\u00a0days), while azithromycin has the shortest time (8.1\u00a0days). The umbrella review included seven systematic reviews, with five focusing on anticancer therapy. Their findings on DIA-associated drugs, including protein kinase inhibitors and immune checkpoint inhibitors, were consistent with those from the disproportionality analysis. Antibiotics, antithyroid drugs, and psychotropic drugs were also identified as causative drugs of DIA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study systematically reviewed the FAERS database and existing literature on DIA to identify a spectrum of associated drugs. Anticancer drugs were predominant, with targeted therapies comprising a large proportion, while non-chemotherapy drugs were also identified as suspect drugs. These findings underscored the need for heightened clinical vigilance toward suspected drugs and highlighted the importance of future efforts to validate high-risk mechanisms and explore DIA monitoring strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1641747","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:44:28Z","timestamp":1758087868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug-induced agranulocytosis: a disproportionality analysis and umbrella review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yajie","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (how long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1046\/j.1365-2249.2002.01720.x","article-title":"Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity","volume":"127","author":"Akamizu","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"657 EP","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andr\u00e8s","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ejim.2006.07.012","article-title":"Idiosyncratic drug-induced agranulocytosis: update of an old disorder","volume":"17","author":"Andr\u00e8s","year":"2006","journal-title":"Eur. J. Intern. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1517\/14740338.7.4.481","article-title":"Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis","volume":"7","author":"Andr\u00e8s","year":"2008","journal-title":"Expert Opin. Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/qjmed\/hcw220","article-title":"Idiosyncratic drug-induced neutropenia and agranulocytosis","volume":"110","author":"Andr\u00e8s","year":"2017","journal-title":"QJM"},{"key":"B8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Rationale, strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective","volume":"27","author":"Azoulay","year":"2022","journal-title":"Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/nrendo.2013.193","article-title":"Diagnosis and management of graves disease: a global overview","volume":"9","author":"Bartalena","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"877932","DOI":"10.3389\/fphar.2022.877932","article-title":"Antibiotic-Induced neutropenia in pediatric patients: new insights from pharmacoepidemiological analyses and a systematic review","volume":"13","author":"Battini","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.3390\/molecules26113255","article-title":"Deferoxamine B: a natural, excellent and versatile metal chelator","volume":"26","author":"Bellotti","year":"2021","journal-title":"Mol. (Basel Switz.)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12885-020-06763-y","article-title":"Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect","volume":"20","author":"Boegeholz","year":"2020","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"612259","DOI":"10.3389\/fphar.2020.612259","article-title":"Inflammasome targeted therapy in pregnancy: new insights from an analysis of real-world data from the FAERS database and a systematic review","volume":"11","author":"Carnovale","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1182\/asheducation-2017.1.187","article-title":"Non\u2013chemotherapy drug\u2013induced neutropenia: key points to manage the challenges","volume":"2017","author":"Curtis","year":"2017","journal-title":"Hematology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/S2666-7568(22)00214-8","article-title":"Strengthening evidence-based medicine with real-world evidence","volume":"3","author":"Dreyer","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.lpm.2008.03.013","article-title":"Idiosyncratic drug-induced agranulocytosis","volume":"37","author":"Federici","year":"2008","journal-title":"Presse Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/CJI.0000000000000293","article-title":"Immune-related neutropenia following treatment with immune checkpoint inhibitors","volume":"43","author":"Finkel","year":"2020","journal-title":"J. Immunother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1517\/14740338.6.3.323","article-title":"Non-chemotherapy drug-induced agranulocytosis","volume":"6","author":"Garbe","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1978 EP","DOI":"10.1111\/bcp.15170","article-title":"Acute antibiotically induced neutropenia: a systematic review of case reports","volume":"88","author":"Holz","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1525 EP","DOI":"10.1007\/s00384-022-04214-7","article-title":"Hematologic toxicities of sunitinib in patients with gastrointestinal stromal tumors: a systematic review and meta-analysis","volume":"37","author":"Jiang","year":"2022","journal-title":"Int. J. Colorectal Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/17425255.2015.985649","article-title":"Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis","volume":"11","author":"Johnston","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ndt\/gfu258","article-title":"Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature","volume":"30","author":"Kamei","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"B25","doi-asserted-by":"publisher","first-page":"19336","DOI":"10.1038\/s41598-023-46307-5","article-title":"Antithyroid drug-induced leukopenia and G-CSF administration: a long-term cohort study","volume":"13","author":"Kamitani","year":"2023","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12282-017-0818-4","article-title":"Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis","volume":"25","author":"Kassem","year":"2018","journal-title":"Breast Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.3390\/ijms24054970","article-title":"Deferiprone and iron-maltol: forty years since their discovery and insights into their drug design, development, clinical use and future prospects","volume":"24","author":"Kontoghiorghes","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/bloodadvances.2021004938","article-title":"Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study","volume":"6","author":"Kwiatkowski","year":"2022","journal-title":"Blood Adv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e01596-22","DOI":"10.1128\/aac.01596-22","article-title":"Antibiotic-Induced neutropenia in patients receiving outpatient parenteral antibiotic therapy: a retrospective cohort Study","volume":"67","author":"Lam","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1152\/physrev.00012.2018","article-title":"The neutrophil\u2019s role during health and disease","volume":"99","author":"Liew","year":"2019","journal-title":"Physiol. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/14740338.2016.1146675","article-title":"Risk of chemotherapy-induced neutropenic complications when treating patients with Non-Hodgkin lymphoma","volume":"15","author":"Lyman","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S2352-3026(20)30100-9","article-title":"Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial","volume":"7","author":"Maggio","year":"2020","journal-title":"Lancet Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.5694\/j.1326-5377.1991.tb93847.x","article-title":"Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal","volume":"155","author":"Mayall","year":"1991","journal-title":"Med. J. Aust."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.3390\/cancers15204940","article-title":"Anaplastic lymphoma kinase inhibitor-induced neutropenia: a systematic review","volume":"15","author":"Moinard-Butot","year":"2023","journal-title":"Cancers"},{"key":"B37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/OP.2023.19.11_suppl.289","article-title":"Patient characteristics associated with myelosuppression among patients with extensive-stage small cell lung cancer treated with chemotherapy in the community oncology setting","volume":"19","author":"Monnette","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"111606","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: a pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.7150\/thno.59092","article-title":"Targeting iron metabolism in cancer therapy","volume":"11","author":"Morales","year":"2021","journal-title":"Theranostics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/S2352-3026(14)00027-1","article-title":"Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study","volume":"2","author":"Nicolini","year":"2015","journal-title":"Lancet Haematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3389\/fimmu.2020.01354","article-title":"Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"11","author":"Omar","year":"2020","journal-title":"Front. Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B43","doi-asserted-by":"publisher","first-page":"105147","DOI":"10.1016\/j.msard.2023.105147","article-title":"Neutropaenia complications from Ocrelizumab and Rituximab treatment","volume":"81","author":"Pang","year":"2024","journal-title":"Multiple Scler. Relat. Disord."},{"key":"B44","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1084\/jem.115.4.821","article-title":"Hypersensitivity to penicillenic acid derivatives in human beings with penicillin allergy","volume":"115","author":"Parker","year":"1962","journal-title":"J. Exp. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1001\/jama.1969.03160100052013","article-title":"Agranulocytosis induced by certain phenothiazine derivatives","volume":"208","author":"Pisciotta","year":"1969","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2165\/00003495-197815020-00003","article-title":"Drug-induced agranulocytosis","volume":"15","author":"Pisciotta","year":"1978","journal-title":"Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1415748","DOI":"10.3389\/fonc.2024.1415748","article-title":"Case report: a rare case of anti-PD-1 sintilimab-induced agranulocytosis\/severe neutropenia in non-small cell lung cancer and literature review","volume":"14","author":"Qin","year":"2024","journal-title":"Front. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"727717","DOI":"10.3389\/fphar.2021.727717","article-title":"Drug-induced idiosyncratic agranulocytosis - infrequent but dangerous","volume":"12","author":"Rattay","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1080\/10428194.2021.1948037","article-title":"Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity","volume":"62","author":"Shimony","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"B51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2016.06.026","article-title":"Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab","volume":"99","author":"Tabchi","year":"2016","journal-title":"Lung Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ajh.21433","article-title":"Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management","volume":"84","author":"Tesfa","year":"2009","journal-title":"Am. J. Hematol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1021\/tx00044a007","article-title":"Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis","volume":"8","author":"Uetrecht","year":"1995","journal-title":"Chem. Res. Toxicol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14740338.2019.1604682","article-title":"Pediatric drug safety signal detection of non-chemotherapy drug-induced neutropenia and agranulocytosis using electronic healthcare records","volume":"18","author":"Wei","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1525307","DOI":"10.3389\/fphar.2025.1525307","article-title":"Non-chemotherapy drugs inducing agranulocytosis: a disproportionality analysis based on the FAERS database","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1507\/endocrj.EJ24-0135","article-title":"Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil","volume":"71","author":"Yoshimura Noh","year":"2024","journal-title":"Endocr. J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B59","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12519-022-00593-7","article-title":"Neutropenia: diagnosis and management","volume":"18","author":"Zhang","year":"2022","journal-title":"World J. Pediatr. WJP"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1231320","DOI":"10.3389\/fphar.2023.1231320","article-title":"Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1641747\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:44:29Z","timestamp":1758087869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1641747\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":60,"alternative-id":["10.3389\/fphar.2025.1641747"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1641747","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1641747"}}